THIS PROMOTIONAL MATERIAL IS INTENDED FOR UK HEALTHCARE PROFESSIONALS ONLY. DO NOT GIVE THE DOCUMENT TO PATIENTS OR THE GENERAL PUBLIC.

Prescribing Information: Great Britain | Northern Ireland

By clicking the links above, you will leave this page and be taken to the EMC PI portal website.



GARDASIL.9 Human Papillomavirus 9-valent Vaccine, Recombinant

Prepare your practice to deliver HPV vaccination to eligible young people who have missed their vaccination in school

Set HPV immunisation goals in your practice

Examples could include:



Ensuring all potentially eligible people registered in the GP practice have been vaccinated against HPV



Maximising practice remuneration by ensuring

systems are in place to claim payment for HPV vaccination activity^{1,2}

02 Ensure HPV immunisation delivery arrangements are in place



Identify a named lead member of staff with responsibility for the immunisation service and ensure all practice staff know who this lead person is¹



Ensure a registered healthcare professional trained and competent in immunisation is available all or most of the time the GP practice is open¹



MSD

Ensure timely appointments that are convenient to the eligible practice population¹

03 Identify people who are potentially eligible to receive HPV vaccination



Create a system for identifying those potentially eligible for HPV vaccination who may attend the practice for other reasons, such as an appointment with the GP or physiotherapist. An example could be using IT alerts to remind staff to discuss HPV vaccination with potentially eligible people



If HPV immunisation is not recorded on an eligible patient's GP record, check the HPV immunisation status with the local Child Health Information System or Child Health department¹

O4 Ensure all GP staff are aware of their responsibilities when it comes to HPV vaccination

Responsibilities could include:



Checking in advance HPV immunisation history

of young people attending the practice for other vaccinations, such as annual influenza vaccination, or healthcare provisions, such as cervical cancer screening, contraceptive reviews and medication reviews




Ensuring local healthcare providers who may engage with young people, such as pharmacists, physiotherapists and opticians, are aware that your GP practice offers HPV vaccination to eligible young people aged between 14 and 25 years who have missed their HPV vaccination in school



Ensuring practice business meetings **include HPV vaccination on the agenda**

12–13 years

Ensure people aged 12–13 years are referred to the School Age Immunisation Services



Ensure groups eligible for vaccination via sexual health services are informed of this arrangement





Want to learn more?

Click on the link below to access more resources on HPV including:

What is HPV and its associated risks? What is the impact of HPV vaccination to date? How can you improve HPV vaccination uptake?

Clicking the link above will take you to a promotional MSD webpage

Gardasil[®] 9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases:^{3,4}

- Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV types
- Genital warts (Condyloma acuminata) caused by specific HPV types

Please refer to the Summary of Product Characteristics for further information prior to making any prescribing decisions.^{3,4}

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Merck Sharp & Dohme Limited (Tel: 0208 154 8000). By clicking the above link, you will leave the MSD website and be taken to the MHRA website.

References: 1. NHS England and NHS Improvement. GP letter on vaccination and immunisation changes for 2021/22. March 2021. Available at: https://www.england.nhs.uk/wp-content/uploads/2021/03/B0434_Update-on-vaccination-and-immunisation-changes-for-202122-v4.pdf. Last accessed: July 2023. **2.** NHS England. Changes to the GP Contract in 2023/24. Available at: <u>https://www.england.nhs.uk/long-read/changes-to-the-gp-contract-in-2023-24/#immunisations-and-vaccinations</u>. Last accessed: July 2023. **3.** Gardasil® 9 (Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed). Summary of Product Characteristics (SPC) for GB. Available at: <u>https://www.emcpi.com/pi/32240</u>. Last accessed: July 2023 **4.** Gardasil® 9 (Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed). Summary of Product Characteristics (SPC) for GB. Available at: <u>https://www.emcpi.com/pi/32240</u>. Last accessed: July 2023 **4.** Gardasil® 9 (Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed). Summary of Product Characteristics (SPC) for GB. Available at: <u>https://www.emcpi.com/pi/32240</u>. Last accessed: July 2023 **4.** Gardasil® 9 (Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed). Summary of Product Characteristics (SPC) for NI. Available at: <u>https://www.emcpi.com/pi/ni/496</u>. Last accessed: July 2023.

Merck Sharp & Dohme (UK) Limited Registered Office: 120 Moorgate, London, EC2M 6UR, United Kingdom. Registered in England No. 233687 © Merck Sharp & Dohme (UK) Limited 2023. All rights reserved. GB-GSL-00385 | August 2023

